• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NanoViricides, Inc. Common Stock (NY:NNVC)

1.120 -0.090 (-7.44%)
Official Closing Price Updated: 8:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 429,400
Open 1.210
Bid (Size) 1.140 (200)
Ask (Size) 1.250 (28,900)
Prev. Close 1.210
Today's Range 1.120 - 1.230
52wk Range 0.9400 - 2.230
Shares Outstanding 15,641,611
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
2 Small-Cap Biotechs That Could Reward Patient Investors ↗
December 12, 2025
Via MarketBeat
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Signs Master Services Agreement With Only Orphans Cote for NV-387 Orphan Drug Strategy
December 01, 2025
Via Investor Brand Network
Topics Intellectual Property

Performance

YTD
-7.4%
-7.4%
1 Month
-13.8%
-13.8%
3 Month
-17.6%
-17.6%
6 Month
-30.0%
-30.0%
1 Year
-17.0%
-17.0%

More News

Read More
News headline image
NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles
December 01, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Files Quarterly Report Highlighting Broad-Spectrum Antiviral Candidate NV-387
November 17, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position
November 17, 2025
Via ACCESS Newswire
News headline image
NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2
November 14, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Closes $6 Million Registered Direct Offering With Concurrent Private Placement of Warrants
November 13, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
November 12, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Announces $6 Million Registered Direct Offering with Concurrent Private Placement of Warrants
November 11, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
November 11, 2025
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
November 10, 2025
Via Benzinga
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Receives Regulatory Approval to Begin Phase II Trial of NV-387 for Treatment of MPox in the DRC
November 10, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo
November 10, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Announces Date and Location of 2025 Annual Shareholders Meeting
November 05, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT
November 05, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at Spartan Capital Investor Conference 2025
November 03, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd
November 03, 2025
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Highlights Potent Anti-Measles Results for NV-387 in Proactive Interview
October 29, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive
October 29, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at PODD 2025 Conference in Boston
October 27, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
October 27, 2025
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Strong Antiviral and Lung-Protective Activity of NV-387 Against Measles
October 23, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides
October 22, 2025
Via ACCESS Newswire
News headline image
A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus
October 20, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Featured in Analyst Report Highlighting Dual-Track Clinical Strategy for NV-387
October 15, 2025
Via Investor Brand Network
Topics Intellectual Property

Frequently Asked Questions

Is NanoViricides, Inc. Common Stock publicly traded?
Yes, NanoViricides, Inc. Common Stock is publicly traded.
What exchange does NanoViricides, Inc. Common Stock trade on?
NanoViricides, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for NanoViricides, Inc. Common Stock?
The ticker symbol for NanoViricides, Inc. Common Stock is NNVC on the New York Stock Exchange
What is the current price of NanoViricides, Inc. Common Stock?
The current price of NanoViricides, Inc. Common Stock is 1.120
When was NanoViricides, Inc. Common Stock last traded?
The last trade of NanoViricides, Inc. Common Stock was at 01/09/26 08:00 PM ET
What is the market capitalization of NanoViricides, Inc. Common Stock?
The market capitalization of NanoViricides, Inc. Common Stock is 17.52M
How many shares of NanoViricides, Inc. Common Stock are outstanding?
NanoViricides, Inc. Common Stock has 18M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap